[go: up one dir, main page]

AR130916A1 - Anticuerpo anti-gucy2c y usos del mismo - Google Patents

Anticuerpo anti-gucy2c y usos del mismo

Info

Publication number
AR130916A1
AR130916A1 ARP230102905A ARP230102905A AR130916A1 AR 130916 A1 AR130916 A1 AR 130916A1 AR P230102905 A ARP230102905 A AR P230102905A AR P230102905 A ARP230102905 A AR P230102905A AR 130916 A1 AR130916 A1 AR 130916A1
Authority
AR
Argentina
Prior art keywords
seq
amino acid
acid sequence
nos
sequence selected
Prior art date
Application number
ARP230102905A
Other languages
English (en)
Inventor
Torsten Hechler
Andreas Pahl
Stephanie Voss
Christian Orlik
Original Assignee
Heidelberg Pharma Res Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Heidelberg Pharma Res Gmbh filed Critical Heidelberg Pharma Res Gmbh
Publication of AR130916A1 publication Critical patent/AR130916A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6831—Fungal toxins, e.g. alpha sarcine, mitogillin, zinniol or restrictocin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6863—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from stomach or intestines cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6871—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an enzyme
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

En un primer aspecto, la presente solicitud se refiere a un anticuerpo antiGUCY2C, comprendiendo los correspondientes conjugados anticuerpo-fármaco amatoxina para su uso en el tratamiento de cánceres gastrointestinales, tales como cáncer colorrectal y cáncer de páncreas. En un segundo aspecto, la presente invención se refiere a composiciones farmacéuticas que comprenden los conjugados anticuerpo-fármaco de la invención para su uso en el tratamiento del cáncer gastrointestinal. La presente invención también se refiere a métodos de tratamiento del cáncer gastrointestinal usando los conjugados anticuerpo-fármaco de la invención. Reivindicación 1: Un anticuerpo aislado o fragmento de anticuerpo que se une específicamente a la guaniliciclasa 2C (GUCY2C), en donde el anticuerpo comprende una región variable de cadena pesada (VH) que comprende una región marco 1 (FRH1), región determinante de la complementariedad 1 (CDRH1), una FRH2, una CDRH2, una FRH3, una CDRH3 y una FRH4, en donde FRH1 comprende una secuencia de aminoácidos seleccionada entre las SEQ ID Nº 33, 40, 45, 51; CDRH1 comprende una secuencia de aminoácidos seleccionada entre las SEQ ID Nº 34, 41, 46, 52; FRH2 comprende una secuencia de aminoácidos según las SEQ ID Nº 35; 55; CDRH2 comprende una secuencia de aminoácidos seleccionada entre las SEQ ID Nº 36, 42, 47; 120; FRH3 comprende una secuencia de aminoácidos seleccionada entre las SEQ ID Nº 37, 43, 48, 53; CDRH3 comprende una secuencia de aminoácidos seleccionada entre las SEQ ID Nº 38, 44, 49; 54; FRH4 comprende una secuencia de aminoácidos seleccionada entre las SEQ ID Nº 39, 50; en donde el anticuerpo comprende una región variable de cadena ligera (VL) que comprende una región marco 1 (FRL1), región determinante de la complementariedad (CDRL1), una FRL2, una CDRL2, una FRL3, una CDRL3 y una FRL4, en donde FRL1 comprende una secuencia de aminoácidos seleccionada entre las SEQ ID Nº 1, 13, 20, 27; CDRL1 comprende una secuencia de aminoácidos seleccionada entre las SEQ ID Nº 2, 14, 21, 28; FRL2 comprende una secuencia de aminoácidos seleccionada entre las SEQ ID Nº 3, 15, 29; CDRL2 comprende una secuencia de aminoácidos seleccionada entre las SEQ ID Nº 4, 16, 23, 30; FRL3 comprende una secuencia de aminoácidos seleccionada entre las SEQ ID Nº 5, 8, 17, 24, 31; CDRL3 comprende una secuencia de aminoácidos seleccionada entre las SEQ ID Nº 6, 9, 11, 18, 25, 32; FRL4 comprende una secuencia de aminoácidos seleccionada entre las SEQ ID Nº 7, 10, 12, 19, 26. Reivindicación 15: Un conjugado que comprende (i) el anticuerpo de acuerdo con una cualquiera de las reivindicaciones 1 - 14, (ii) al menos una toxina y (iii) al menos un enlazador que conecta dicho resto de anticuerpo don dicha al menos una toxina, en donde dicho anticuerpo se une específicamente a GUCY2C humano y en donde dicha al menos una toxina es una amatoxina.
ARP230102905A 2022-11-01 2023-10-31 Anticuerpo anti-gucy2c y usos del mismo AR130916A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP22204963 2022-11-01

Publications (1)

Publication Number Publication Date
AR130916A1 true AR130916A1 (es) 2025-01-29

Family

ID=84330056

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP230102905A AR130916A1 (es) 2022-11-01 2023-10-31 Anticuerpo anti-gucy2c y usos del mismo

Country Status (11)

Country Link
US (1) US20240165257A1 (es)
EP (1) EP4611897A1 (es)
KR (1) KR20250099224A (es)
CN (1) CN120187759A (es)
AR (1) AR130916A1 (es)
AU (1) AU2023374571A1 (es)
CL (1) CL2025001036A1 (es)
CO (1) CO2025004991A2 (es)
IL (1) IL320168A (es)
MX (1) MX2025004144A (es)
WO (1) WO2024094688A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4566631A1 (en) 2023-12-06 2025-06-11 Heidelberg Pharma Research GmbH New antibody drug conjugate as well as methods of production and uses thereof

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI102355B1 (fi) 1988-02-11 1998-11-30 Bristol Myers Squibb Co Menetelmä yhdistävän välikappaleen omaavien antrasykliini-immunokonjugaattien valmistamiseksi
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
DE69626849T2 (de) 1995-12-22 2003-12-24 Bristol-Myers Squibb Co., Princeton Verzweigte hydrazongruppen enthaltende kuppler
EP1212422B1 (en) 1999-08-24 2007-02-21 Medarex, Inc. Human ctla-4 antibodies and their uses
EP1427744B1 (en) 2001-08-27 2007-12-26 Genentech, Inc. A system for antibody expression and assembly
WO2003026577A2 (en) 2001-09-24 2003-04-03 Seattle Genetics, Inc. P-amidobenzylethers in drug delivery agents
WO2005112919A2 (en) 2004-05-19 2005-12-01 Medarex, Inc. Self-immolative linkers and drug conjugates
EP3088004B1 (en) 2004-09-23 2018-03-28 Genentech, Inc. Cysteine engineered antibodies and conjugates
EP2439273B1 (en) 2005-05-09 2019-02-27 Ono Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
AU2008251608B2 (en) 2007-05-08 2014-03-27 Genentech, Inc. Cysteine engineered anti-MUC16 antibodies and antibody drug conjugates
NZ600758A (en) 2007-06-18 2013-09-27 Merck Sharp & Dohme Antibodies to human programmed death receptor pd-1
JP5606916B2 (ja) 2007-10-19 2014-10-15 ジェネンテック， インコーポレイテッド システイン操作抗ｔｅｎｂ２抗体および抗体薬物結合体
RU2531758C2 (ru) 2008-02-11 2014-10-27 Куретек Лтд. Моноклональные антитела для лечения опухолей
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
US8217149B2 (en) 2008-12-09 2012-07-10 Genentech, Inc. Anti-PD-L1 antibodies, compositions and articles of manufacture
LT3279215T (lt) 2009-11-24 2020-04-10 Medimmune Limited Tiksliniai surišantys agentai prieš b7-h1
LT2785375T (lt) 2011-11-28 2020-11-10 Merck Patent Gmbh Anti-pd-l1 antikūnai ir jų panaudojimas
KR102046435B1 (ko) 2012-04-27 2019-11-19 밀레니엄 파머슈티컬스 인코퍼레이티드 항-gcc 항체 분자 및 gcc-표적화 치료법에 대한 감수성을 평가하기 위한 그 용도
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
EP3388449A3 (en) 2014-09-12 2018-10-24 F. Hoffmann-La Roche AG Cysteine engineered antibodies and conjugates
SI3268047T1 (sl) 2015-03-09 2024-02-29 Heidelberg Pharma Research Gmbh Konjugati amatoksin-protitelo
EP3222292A1 (en) 2016-03-03 2017-09-27 Heidelberg Pharma GmbH Amanitin conjugates
WO2018115466A1 (en) 2016-12-23 2018-06-28 Heidelberg Pharma Research Gmbh Amanitin antibody conjugates
CN110691790A (zh) 2017-06-02 2020-01-14 勃林格殷格翰国际有限公司 抗癌联合治疗
PT3665173T (pt) 2017-08-07 2025-06-11 Heidelberg Pharma Res Gmbh Novo método para sintetizar amanitinas
EP3773740A1 (en) 2018-04-13 2021-02-17 Heidelberg Pharma Research GmbH Targeted amatoxin conjugate for the treatment of solid tumors
KR102584675B1 (ko) * 2018-05-23 2023-10-05 화이자 인코포레이티드 GUCY2c에 특이적인 항체 및 이의 용도
JP2022530026A (ja) 2019-04-24 2022-06-27 ハイデルベルク ファルマ リサーチ ゲゼルシャフト ミット ベシュレンクテル ハフツング アマトキシン抗体薬物複合体及びその使用
WO2021205325A1 (en) 2020-04-08 2021-10-14 Pfizer Inc. Anti-gucy2c antibodies and uses thereof
GB2595299B (en) 2020-05-21 2022-08-03 Mabsolve Ltd Modified immunoglobulin FC regions
CN116744969A (zh) 2020-11-04 2023-09-12 海德堡医药研究有限责任公司 用于癌症疗法的包含免疫检查点抑制剂与抗体-鹅膏毒素缀合物的组合的组合物

Also Published As

Publication number Publication date
IL320168A (en) 2025-06-01
EP4611897A1 (en) 2025-09-10
WO2024094688A1 (en) 2024-05-10
KR20250099224A (ko) 2025-07-01
CL2025001036A1 (es) 2025-05-30
CN120187759A (zh) 2025-06-20
AU2023374571A1 (en) 2025-04-03
US20240165257A1 (en) 2024-05-23
MX2025004144A (es) 2025-05-02
CO2025004991A2 (es) 2025-05-19

Similar Documents

Publication Publication Date Title
JP2023129543A5 (es)
IL290591B1 (en) Antibody drug conjugates (adc) that bind to 191p4d12 proteins
JP2020506900A5 (es)
HRP20170407T1 (hr) Anti-epha2 anitijelo
AR127344A2 (es) Conjugados anticuerpo-fármaco que comprenden agonistas de sting
PE20090518A1 (es) Proteinas enlazantes de antigenos que enlazan al receptor de la interleucina 18 (il-18)
PE20081185A1 (es) Anticuerpos que se unen a interleucina 13 (il-13) humana y composiciones farmaceuticas que lo comprenden
RU2588467C3 (ru) Стабильные и растворимые антитела, ингибирующие vegf
IL268745A (en) Antibody drug conjugates (adc) that bind to 158p1d7 proteins
HRP20240182T1 (hr) Ljudska monoklonska protutijela za teški akutni respiratorni sindrom koronavirusa 2 (sars-cov-2)
HRP20160082T1 (hr) Sastavi i postupci za dijagnosticiranje i lijeäśenje raka
PE20020292A1 (es) Anticuerpos que tienen especificidad por el factor de necrosis tumoral
PE20131400A1 (es) Proteinas de union a antigeno contra proproteina converstasa subtilisina/kexina tipo 9 (pcsk9)
RU2014143784A (ru) Фармацевтическая композиция для лечения и/или предотвращения рака желчного пузыря
RU2022111211A (ru) Конъюгаты анти-cd71 активируемое антитело - лекарственное средство и способы их применения
AR080698A1 (es) Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e
PE20160651A1 (es) Proteinas de union a il-17
RU2015101803A (ru) Перекрестно реактивные антитела к jagged 1/k jagged 2, активируемые антитела к jagged и способы их применения
PE20221151A1 (es) Anticuerpos anti-cd96 y sus metodos de uso
JP2020537649A5 (es)
PE20220568A1 (es) Moleculas de union a cd19 y usos de las mismas
AR130916A1 (es) Anticuerpo anti-gucy2c y usos del mismo
HRP20220550T1 (hr) Imunokonjugati koji ciljaju adam9 i postupci njihove uporabe
RU2020112280A (ru) Конъюгаты анти-egfr антитело-лекарственное средство (adc) и их применение
PE20230844A1 (es) Anticuerpo anti-nectina-4, conjugado que lo incluye y aplicacion de los mismos